FDA investigators find no safety risks when switching between biologics, biosimilars

Switching between biosimilars and reference products did not increase the risk for death or serious adverse events, according to a meta-analysis conducted by FDA investigators.
“Increasing the availability and use of biosimilars is an important public health strategy for reducing drug costs and increasing the availability of biological products to underserved populations,” Thomas M. Herndon, MD, of the FDA’s Office of Therapeutic Biologics and Biosimilars, and colleagues wrote in PLS One. “Despite the adoption of biosimilars in many therapeutic areas, concerns persist

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart